Clinical Trials Logo

Telangiectasis clinical trials

View clinical trials related to Telangiectasis.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT02309632 Withdrawn - Clinical trials for Pancreatic Neoplasms

Pancreatic Cancer Screening of High-Risk Individuals in Arkansas

Start date: November 2015
Phase: N/A
Study type: Interventional

100 subjects who have a family history of pancreatic cancer (PC), or known genetic syndromes associated with increased risk of pancreatic cancer, will be followed for five years. This data will be used to determine the pancreatic cancer and precancerous lesion detection rate in High Risk Individuals (HRIs). Subjects may agree to annual imaging and annual biomarkers or to biomarkers only.

NCT ID: NCT02090517 Withdrawn - Telangiectasis Clinical Trials

Laser Therapy Versus Electrosurgery For Nasal Telangiectasias

Start date: June 2014
Phase: N/A
Study type: Interventional

The aim of this study is to compare the efficacy of various treatment options for eliminating nasal telangiectasias. The study will compare the outcome of treating nasal telangiectasias with the following; no treatment (control site), alexandrite laser, pulsed dye laser, combination pulsed dye laser and Nd:YAG 1064nm multiplex laser system and electrosurgery.

NCT ID: NCT01406639 Withdrawn - Clinical trials for Hereditary Hemorrhagic Telangiectasia (HHT)

Ranibizumab for the Management of Recurrent Nosebleeds in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

Start date: July 2011
Phase: Phase 1
Study type: Interventional

This study is for patients with recurrent epistaxis (nosebleeds) as a result of Hereditary Hemorrhagic Telangiectasia (HHT). The aim is to determine if ranibizumab, topically applied will diminish epistaxis in patients with HHT as measured by the HHT Epistaxis Severity Score (ESS), hematocrit, and hemoglobin and serum ferritin levels.

NCT ID: NCT00733629 Withdrawn - Clinical trials for Telangiectasia, Hereditary Hemorrhagic

Study of Endothelial Cells in Patients With Hereditary Haemorrhagic Telangiectasia

Start date: August 2002
Phase:
Study type: Observational

Hereditary Haemorrhagic Telangiectasia (HHT, also known as Osler-Weber-Rendu Syndrome) is an disease that leads to the development of dilated and fragile blood vessels. We propose to culture endothelial cells from patients with HHT, to culture cells that express the proteins mutated in HHT, namely endoglin and ALK-1. We will study the properties of these cells which will involve their growth in different conditions and anticipate that DNA, mRNA and proteins will be extracted from these cells for study of cell responses and association with expression levels of endoglin and ALK-1. We hypothesize that these cells which express "half-normal" endoglin or ALK-1 will show altered protein synthetic differences when compared to normal white blood cells. We anticipate that that these findings may help to explain aspects of the HHT disease phenotype.